The most common form of cancer treatment is the use of small-molecule chemotherapeutic agents. However, due to non-specific distribution and uptake, these drugs have a host of complications that limit their efficacy and usage. Polymer nanocarriers have been demonstrated to improve drug pharmacokinetics, enhancing therapeutic benefit of the drugs. The feasibility of cyclic micelle-like polymer nanoparticles for use as a delivery vehicle for doxorubicin (abbreviated as DOX), a potent chemotherapeutic drug, is discussed here. It is hypothesized that cyclic polymers will afford a more efficacious pharmacokinetic release profile than their linear counterparts. A linear polymer is functionalized with “click”able moieties at each end, which are then joined to create a single cyclized polymer. The polymer is decorated with poly(ethylene glycol) (PEG) chains to reduce immunogenicity, and carboxylic acid groups to electrostatically complex with the positively-charged DOX molecule. Upon addition of DOX, the polymer self-assembles into unimolecular micelle-like structures. When the construct accumulates in a tumor microenvironment due to the enhanced permeability and retention (EPR) effect, the low pH of the tumoral interstitium protonates the carboxylic acid groups, releasing DOX locally. Using a unimolecular micelle-like approach, less polymer can be used to deliver the same therapeutic payload, relative to other similar approaches that utilize pluralities of potentially toxic polymers to form micelle structures. The polymer’s average molecular weight is around 11530 Da and the polydispersity of the reaction is 1.067. Gel Permeation Chromatography, Nuclear Magnetic Resonance, Fourier-Transform Infrared Spectroscopy, Ultraviolet-Visible Spectroscopy and Dynamic Light Scattering are used to confirm chemical identity, drug loading efficiency, particle size, and polydispersity. Cytotoxicity studies conducted with MDA-MB-231 invasive ductal carcinoma cells in vitro demonstrate the feasibility of this construct.